Key Points
- Rui Avelar, an Evolus insider, sold 3,119 shares on March 20 at an average price of $4.75 for $14,815, reducing his stake by 0.72% to 427,423 shares (valued at about $2.03M).
- Avelar has been selling repeatedly this season, including a larger sale of 29,996 shares on March 17 at $4.89 and 2,261 shares on December 22 at $7.15, signaling continued insider disposition.
- Evolus shares opened at $4.64 and were trading down ~4.5%, with a 12-month range of $4.09–$13.30 and a market cap of ~$302M; the company missed EPS expectations in the most recent quarter ($0.00 vs. $0.09) while revenue roughly matched estimates, and analysts show a mixed view with a consensus of “Moderate Buy” and an average target of $16.00.
Evolus, Inc. (NASDAQ:EOLS - Get Free Report) insider Rui Avelar sold 3,119 shares of the firm's stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $4.75, for a total value of $14,815.25. Following the sale, the insider owned 427,423 shares in the company, valued at $2,030,259.25. This trade represents a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Rui Avelar also recently made the following trade(s):
- On Tuesday, March 17th, Rui Avelar sold 29,996 shares of Evolus stock. The stock was sold at an average price of $4.89, for a total value of $146,680.44.
- On Monday, December 22nd, Rui Avelar sold 2,261 shares of Evolus stock. The stock was sold at an average price of $7.15, for a total value of $16,166.15.
Evolus Trading Down 4.5%
Shares of EOLS opened at $4.64 on Friday. Evolus, Inc. has a 12 month low of $4.09 and a 12 month high of $13.30. The stock's 50 day moving average is $4.79 and its two-hundred day moving average is $6.05. The firm has a market cap of $301.88 million, a P/E ratio of -5.73 and a beta of 1.02.
Evolus (NASDAQ:EOLS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported $0.00 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.09). The firm had revenue of $90.30 million during the quarter, compared to analyst estimates of $89.58 million. Equities research analysts forecast that Evolus, Inc. will post -0.61 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on the stock. Weiss Ratings reissued a "sell (e+)" rating on shares of Evolus in a report on Monday, December 22nd. BTIG Research reiterated a "buy" rating and issued a $13.00 target price on shares of Evolus in a research report on Wednesday, March 4th. Wall Street Zen cut shares of Evolus from a "buy" rating to a "hold" rating in a research note on Sunday, March 15th. HC Wainwright reduced their price target on shares of Evolus from $20.00 to $13.00 and set a "buy" rating for the company in a research report on Tuesday, February 3rd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Evolus in a research note on Wednesday, December 24th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Evolus currently has a consensus rating of "Moderate Buy" and an average target price of $16.00.
Read Our Latest Analysis on EOLS
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Braidwell LP purchased a new position in Evolus in the 4th quarter valued at $20,650,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Evolus during the second quarter worth $22,431,000. Nantahala Capital Management LLC raised its position in shares of Evolus by 33.2% in the third quarter. Nantahala Capital Management LLC now owns 5,726,857 shares of the company's stock valued at $35,163,000 after buying an additional 1,428,931 shares during the last quarter. Soleus Capital Management L.P. raised its position in shares of Evolus by 96.4% in the second quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company's stock valued at $19,516,000 after buying an additional 1,039,842 shares during the last quarter. Finally, Armistice Capital LLC purchased a new position in shares of Evolus in the fourth quarter worth about $6,490,000. 90.69% of the stock is owned by institutional investors and hedge funds.
About Evolus
(
Get Free Report)
Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.
The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
